Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 8:2021:9657071.
doi: 10.1155/2021/9657071. eCollection 2021.

Role of miRNA-495 and NRXN-1 and CNTN-1 mRNA Expression and Its Prognostic Importance in Breast Cancer Patients

Ali G Alkhathami  1 , Amit Kumar Verma  2 , Mohammed Alfaifi  1 , Lalit Kumar  3 , Mohammad Yahya Alshahrani  1 , Abdulrahim R Hakami  1 , Osama M Alshehri  4 , Mohammed Asiri  1 , Mirza Masroor Ali Beg  5   6
Affiliations

Role of miRNA-495 and NRXN-1 and CNTN-1 mRNA Expression and Its Prognostic Importance in Breast Cancer Patients

Ali G Alkhathami et al. J Oncol. .

Abstract

Breast cancer is a heterogeneous disease in which genetic factors are involved in disease worsening and higher mortality. Epidemiological and clinical research revealed that breast cancer incidence continues to rise. 100 histopathologically confirmed untreated newly diagnosed cases of invasive ductal carcinoma (IDC) of breast and 100 healthy subjects were involved and blood samples were collected in non-EDTA plain vials. Serum was separated by centrifugation, total RNA was extracted from serum, and cDNA synthesis was done to study the miRNA-495 and neurexin-1 (NRXN-1) and contactin 1 (CNTN-1) mRNA expression by QRT-PCR. The expression levels of miRNA-495, NRXN-1, and CNTN-1 were expressed in fold change. The present study observed decreased relative miRNA-495 expression (0.07-fold) while an increase in NRXN-1 (11.61-fold) and CNTN-1 (4.92-fold) was observed among breast cancer patients compared to healthy controls. A significant difference was observed in miRNA-495 expression with menopausal status (p=0.0001) and TNM stages (p=0.02). It was observed that NRXN-1 expression was significantly associated with menopausal status (p=0.03), lymph node involvement (p < 0.0001), estrogen receptor (ER) status (p=0.03), progesterone receptor (PR) status (p=0.005), TNM stages (p < 0.0001), and distant metastases (p < 0.0001). CNTN-1 expression was also found to be associated with lymph node involvement (p=0.01), PR status (p=0.03), HER2 status (p=0.04), TNM stages (p < 0.0001), and distant metastases (p < 0.0001). ROC suggested that NRXN-1 and CNTN-1 could be the important predictive marker for disease advancement and distant organ metastases. The study concluded that the decreased expression of miR-495 observed in breast cancer patients showed a negative correlation with NRXN-1 while the increased expression of NRXN-1 and CNTN-1 was linked with disease advancement and distant metastases and could be the important predictive marker for breast cancer patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest regarding this study.

Figures

Figure 1
Figure 1
Correlation of miRNA-495 and NRXN-1 mRNA expression among the breast cancer cases.
Figure 2
Figure 2
Correlation of miRNA-497 and CNTN-1 mRNA expression among the breast cancer cases.
Figure 3
Figure 3
Correlation of NRXN-1 and CNTN-1 mRNA expression among the breast cancer cases.
Figure 4
Figure 4
ROC curve: (a) microRNA-495, (b) NRXN-1, and (c) CNTN-1 w.r.t. TNM stages (early stage and advanced stage).
Figure 5
Figure 5
ROC curve: (a) microRNA-495, (b) NRXN-1, and (c) CNTN-1 w.r.t. metastases (no metastases and distant metastases).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mansoori B., Silvestris N., Mohammadi A., et al. miR-34a and miR-200c have an additive tumor-suppressive effect on breast cancer cells and patient prognosis. Genes . 2021;12(2):p. 267. doi: 10.3390/genes12020267. - DOI - PMC - PubMed
    1. Mansoori B., Duijf P. H. G., Mohammadi A., et al. MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy. Life Sciences . 2021;276 doi: 10.1016/j.lfs.2021.119431.119431 - DOI - PubMed
    1. Tapeh B. E. G., Mosayyebi B., Mansoori B., Gravand Z. A., Sarvnaz H., Mohammadi A. Emerging molecular functions of microRNA-9: cancer pathology and therapeutic implications. Anti-Cancer Agents in Medicinal Chemistry . 2021;21 doi: 10.2174/1871520621666210217094839. - DOI - PubMed
    1. Lehmann B. D., Bauer J. A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation . 2011;121(7):2750–2767. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Landskron G., De la Fuente M., Thuwajit P., Thuwajit C., Hermoso M. A. Chronic inflammation and cytokines in the tumor microenvironment. Journal of Immunology Research . 2014;2014:19. doi: 10.1155/2014/149185.149185 - DOI - PMC - PubMed